Newsroom
Thermo Fisher Scientific Announces Launch of Innovative CorEvitas Pharmacovigilance Platform for Clinical Research Registries
WALTHAM, Mass (December 20, 2023) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of CorEvidence, a proprietary cloud-based data lake platform optimizing pharmacovigilance case processing and safety data management processes. The new platform enhances CorEvitas clinical research registries offered by Thermo Fisher’s PPD clinical research business.
CorEvidence’s first application supports enhanced pharmacovigilance workflow and deliverable management. It is designed to handle multiple data sources and streamline coding, classification and reporting of adverse events and safety events of interest for committed post-authorization safety studies. The platform supports a full range of pharmacovigilance deliverables with efficient, traceable, auditable, scalable and compliant safety management for customer safety commitments using data collected through CorEvitas syndicated registries.
“I am excited to see us deliver fit-for-purpose, highly impactful solutions to some of our most challenging and complex pharmacovigilance business needs,” said Christine Barr, vice president of pharmacovigilance, CorEvitas. “We look forward to the positive impact this system will have on our customers and, most importantly, the well-being of the patients and our medical communities who depend on timely availability of real-world evidence and ongoing benefit/risk assessment activities to inform the safe use of pharmaceutical products.”
Thermo Fisher acquired CorEvitas, a leading provider of gold-standard real-world evidence solutions, in August 2023. CorEvitas services include 12 registries, including nine autoimmune and inflammatory syndicated registries, and a data intelligence platform that builds and scales clinical registries across multiple therapeutic areas to gather structured patient clinical data spanning 400 investigator sites and over 100,000 patients followed longitudinally. The CorEvitas model is being leveraged to satisfy regulatory requirements for more than 15 long-term post-authorization safety studies across eight disease indications.
To learn more about CorEvidence, email info@corevitas.com.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Media Contact Information:
Nadine Maeser